Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorSantos, Fernanda Nunes-
Autor(es): dc.creatorBorja-Cabrera, Gulnara Patricia-
Autor(es): dc.creatorMyashiro, L. M.-
Autor(es): dc.creatorGrechi, Juliana-
Autor(es): dc.creatorReis, Alexandre Barbosa-
Autor(es): dc.creatorMoreira, Márcio Antônio Batistela-
Autor(es): dc.creatorMartins Filho, Olindo Assis-
Autor(es): dc.creatorLuvizotto, Maria Cecília Rui-
Autor(es): dc.creatorMenz, Ingrid-
Autor(es): dc.creatorPessôa, L. M.-
Autor(es): dc.creatorGonçalves, Pablo Rodrigues-
Autor(es): dc.creatorPalatnik, Marcos-
Autor(es): dc.creatorSouza, Clarisa Beatriz Palatnik de-
Data de aceite: dc.date.accessioned2019-11-06T13:24:14Z-
Data de disponibilização: dc.date.available2019-11-06T13:24:14Z-
Data de envio: dc.date.issued2012-07-10-
Data de envio: dc.date.issued2012-07-10-
Data de envio: dc.date.issued2007-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/123456789/1042-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/554657-
Descrição: dc.descriptionIn order to assess the immunotherapeutic potential on canine visceral leishmaniasis of the Leishmune ® vaccine, formulated with an increased adjuvant concentration (1 mg of saponin rather than 0.5 mg), 24 mongrel dogs were infected with Leishmania (L.) chagasi . The enriched-Leishmune ® vaccine was injected on month 6, 7 and 8 after infection, when animals were seropositive and symptomatic. The control group were injected with a saline solution. Leishmune ® -treated dogs showed significantly higher levels of anti-FML IgG antibodies (ANOVA; p < 0.0001), a higher and stable IgG2 and a decreasing IgG1 response, pointing to a TH1 T cell mediated response. The vaccine had the following effects: it led to more positive delayed type hypersensitivity reactions against Leishmania lysate in vaccinated dogs (75%) than in controls (50%), to a decreased average of CD4+ Leishmania -specific lymphocytes in saline controls (32.13%) that fell outside the 95% confidence interval of the vaccinees (41.62%, CI95% 43.93–49.80) and an increased average of the clinical scores from the saline controls (17.83) that falls outside the 95% confidence interval for the Leishmune ® immunotherapy-treated dogs (15.75, CI95% 13.97–17.53). All dogs that received the vaccine were clustered, and showed lower clinical scores and normal CD4+ counts, whereas 42% of the untreated dogs showed very diminished CD4+ and higher clinical score. The increase in clinical signs of the saline treated group was correlated with an increase in anti-FML antibodies (p < 0.0001), the parasitological evidence ( p = 0.038) and a decrease inLeishmania -specific CD4+ lymphocyte proportions (p = 0.035). These results confirm the immunotherapeutic potential of the enriched-Leishmune ® vaccine. The vaccine reduced the clinical symptoms and evidence of parasite, modulating the outcome of the infection and the dog’s potential infectiosity to phlebotomines. The enriched-Leishmune ® vaccine was subjected to a safety analysis and found to be well tolerated and safe-
Idioma: dc.languageen-
Direitos: dc.rightsO Periódico Vaccine concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3291410128861.-
Palavras-chave: dc.subjectFML-vaccine-
Palavras-chave: dc.subjectImmunotherapy-
Palavras-chave: dc.subjectLeishmune-
Palavras-chave: dc.subjectvaccine-
Palavras-chave: dc.subjectCanine visceral leishmaniasis-
Título: dc.titleImmunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.